Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. by unknown
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
Identification of a neo-epitope dominating
endogenous CD8 T cell responses to MC-38
colorectal cancer
Brett J. Hos, Marcel G.M. Camps, Jitske van den Bulk, Elena Tondini, Thomas
C. van den Ende, Dina Ruano, Kees Franken, George M.C. Janssen, Arnoud H.
de Ru, Dmitri V. Filippov, Ramon Arens, Peter A. van Veelen, Noel F.C.C. de
Miranda & Ferry Ossendorp
To cite this article: Brett J. Hos, Marcel G.M. Camps, Jitske van den Bulk, Elena Tondini, Thomas
C. van den Ende, Dina Ruano, Kees Franken, George M.C. Janssen, Arnoud H. de Ru, Dmitri V.
Filippov, Ramon Arens, Peter A. van Veelen, Noel F.C.C. de Miranda & Ferry Ossendorp (2019):
Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal
cancer, OncoImmunology, DOI: 10.1080/2162402X.2019.1673125
To link to this article:  https://doi.org/10.1080/2162402X.2019.1673125
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 13 Oct 2019. Submit your article to this journal 
Article views: 1057 View related articles 
View Crossmark data
BRIEF REPORT
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ABSTRACT
The murine MC-38 colorectal cancer model is a commonly used model for cancer with high mutational
burden, which is sensitive for immune checkpoint immunotherapy. We set out to analyze endogenous
CD8+ T cell responses to MC-38 neo-antigens in tumor-bearing mice and after anti-PD-L1 checkpoint
therapy. Through combination of whole-exome sequencing analysis with mass spectrometry of MHC
class I eluted peptides we could identify eight candidate epitopes. Of these, a neo-epitope encoded by
a point-mutation in the sequence of the ribosomal protein L18 (Rpl18) strongly dominated the CD8+
T cell response to our MC-38 cell-line in comparison to a previously described neo-epitope in the Adpgk
protein. Therapeutic vaccination with synthetic peptides induced CD8+ T cell responses against the
mutated Rpl18 epitope, which controlled tumor growth in vivo. This immunologically dominant
response to mutated Rpl18 is of great importance in the development and optimization of immunother-
apeutic strategies with the MC-38 tumor model.
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In recent years, immunotherapy has received major focus as
a novel therapeutic platform for cancer treatment. The field
mainly focuses on the (re-)activation of the adaptive immune
system that becomes suppressed through cancer-induced immu-
nological changes at systemic- and micro-environmental level.1
Cytotoxic CD8+ T cells are the major immune cells, which have
the potential to directly kill cancer cells. Upon alleviation of
suppression by anti-PD-1/PD-L1 and/or anti-CTLA4 antibo-
dies, so-called immune checkpoint inhibitors,2,3 these CD8+
T lymphocytes become effector cells that specifically recognize
tumor cells and thereby improve tumor control.
Tumor-specific CD8+ T cells have been shown to primarily
recognize somatic (bystander) mutations present in the malignant
cells. This is supported by the positive-correlation of mutational
load of tumors, which increases the chance of expressed and
presented epitopes, and thereby therapeutic effectiveness upon
immune checkpoint inhibitor treatment.4–8 Moreover, the central
role of neo-antigen recognition by the adaptive immune system is
reinforcedwith observations in changingmutational landscapes of
tumors through checkpoint inhibition.9–11 Thus, it is now well
accepted that epitopes containing mutations are key to the effec-
tivity of immunotherapy.
Improving cytotoxic T cell activity against mutated epi-
topes is a logical next step to advance immunotherapy. The
field is rapidly making steps forward to optimize specific
personalized immunotherapy, for instance by therapeutic
vaccination.4,12,13 Several issues have to be solved; like the
time-consuming determination of relevant epitopes, formula-
tion, and adjuvant inclusions necessary to trigger efficient
immune responses in suppressed environments.14 Therefore,
good models are required for the future development of
personalized treatment regimes.
In this study, we have explored the immunogenic responses of
themurine adenocarcinomaMC-38 cancermodel targeting neo-
antigens. Herewith, we report dominant CD8+ T cell immune
responses toward a novel, to our knowledge undescribed, neo-
epitope derived from the ribosomal protein L18 (Rpl18). We
could show this neo-epitope response in several settings in
which mice were exposed to MC-38 tumor cells and treated by
immunotherapy. Using synthetic peptides covering the neo-
epitope and flanking sequences, we managed to induce tumor
control inmice through therapeutic vaccination. Compared with
previously describedmutation-specific responses againstMC-38,
our data suggests a major role in tumor control for this neo-
epitope in the Rpl18 protein.
Method and materials
Sequencing and mutation analysis
DNA was isolated from the MC-38 cell line and from the tail of
inbred C57BL/6JIco mice by use of Nucleospin Tissue kit.
Additionally, RNA was isolated from both tissue sources by use
of Trizol. SureSelect Mouse All Exon Kit was used for capture of
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the coding sequences. TruSeq Stranded Total RNA sample pre-
paration kit was used to generate RNAseq libraries. Paired-end,
100bp reads were generated on a HiSeq2000 (Illumina) sequen-
cer, producing approximately 12Gbof data per sample.Mapping
of the sequences was done against the mm10 reference genome
with BWA.15 Variant calling was performed using the paired
tumor-normal mode of Mutect2,16 where the tail DNA of
a C57BL/6J mouse was used as normal. Variants were function-
ally annotated using the ensembl Variant Effect Predictor.17
Variants were selected as potential neo-antigens if non-
synonymous mutations occurred in coding regions and were
supported by at least one read at RNA level. To exclude sequen-
cing artifacts, all selected variants were visually inspected using
IGV.18,19 MHC binding affinity prediction was performed with
NetMHC4.0.20,21 Homology testing was performed with
ProteinBlast to eliminatemutant sequences similar to autologous
germline sequences in the genome.
Tumor cell-line, elution, and mass-spectrometry
MC-38 (kindly provided by Mario P. Colombo) was cultured in
IMDM medium (Lonza) supplemented with 8% Fetal Calf
Serum (Greiner), 100 IU/mL penicillin/streptomycin (Gibco),
2 mM L-glutamine (Gibco) and 25 µM 2-mercaptoethanol
(culture medium). Cell lines were mycoplasma and MAP-
tested before the start of experiments. Approximately 8 × 108
MC-38 cells were lysed in 10 mL lysis buffer (50 mM Tris-Cl
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% Zwittergent 3–12
(N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate)
and protease inhibitor (Complete, Roche Applied Science)) for
2 h at 0°C (ref A). Lysates were successively centrifuged for
10 min at 2500 × g and for 45 min at 31,000 x g to remove
nuclei and other insoluble material, respectively. Next, lysates
were passed through an 800 µL CL-4B Sepharose column to
preclear the lysate. The cleared lysate was passed through
a 800 µL column containing 2 mg anti-Kb (Y3) IgG coupled
to protein A Sepharose22 and subsequently through a 800 µl
column containing 2 mg anti-Db (28-14-8) IgG coupled to
protein A Sepharose. The antibody columns were washed
with 1 mL of lysis buffer, 3 mL of low salt buffer (20 mM Tris-
Cl pH 8.0, 120 mM NaCl), 1 mL of high salt buffer (20 mM
Tris-Cl pH 8.0, 1 M NaCl), and finally with 3 mL of low salt
buffer. Peptides were eluted with 5 mL of 10% acetic acid,
diluted with 10 mL of 0.1% TFA and purified by SPE (Oasis
HLB, Waters) using 20% and 30% acetonitrile in 0.1% TFA to
elute the peptides. Peptides were lyophilized, dissolved in 95/3/
0.1 v/v/v water/acetonitrile/formic acid and subsequently ana-
lyzed by on-line C18 nanoHPLC MS/MS with a system con-
sisting of an Easy nLC 1200 gradient HPLC system (Thermo,
Bremen, Germany), and a LUMOS mass spectrometer
(Thermo). Fractions were injected onto a homemade precol-
umn (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm,
Dr. Maisch, Ammerbuch, Germany) and eluted via
a homemade analytical nano-HPLC column (30 cm × 75 μm;
Reprosil-Pur C18-AQ 3 um). The gradient was run from 2% to
36% solvent B (20/80/0.1 water/acetonitrile/formic acid (FA) v/
v) in 120 min. The nano-HPLC column was drawn to a tip of
∼5 μm and acted as the electrospray needle of the MS source.
The LUMOS mass spectrometer was operated in data-
dependent MS/MS mode for a cycle time of 3 seconds, with
a HCD collision energy at 32 V and recording of the MS2
spectrum in the orbitrap. In the master scan (MS1) the resolu-
tion was 60,000, the scan range 300–1400, at an AGC target of
400,000 at maximum fill time of 50 ms. Dynamic exclusion
after n = 1 with exclusion duration of 20 s. Charge states 1–4
were included. For MS2 precursors were isolated with the
quadrupole with an isolation width of 1.2 Da. First mass was
set to 110 Da. The MS2 scan resolution was 30,000 with an
AGC target of 50,000 at maximum fill time of 100 ms. In
a post-analysis process, raw data were first converted to peak
lists using Proteome Discoverer version 2.1 (Thermo Electron),
and then submitted to the Uniprot Mus Musculus database
(52015 entries), using Mascot v. 2.2.04 (www.matrixscience.
com) for protein identification. Mascot searches were with 10
ppm and 0.02 Da deviation for precursor and fragment mass,
respectively, and no enzyme was specified. Methionine oxida-
tion was set as a variable modification. Peptides with MASCOT
scores <35 were generally discarded. For PRM analyses, the
samples were lyophilized and resuspended in buffer A. The
ligandome of 100 E6 cell equivalents was injected together
with a mix of 20 fmol of each heavy labeled peptide. The
Orbitrap Fusion LUMOS mass spectrometer was operated in
PRM-mode. Peptides ASMTNMELM and KILTFDRL were
monitored. The normalized collision energy was set to 32%.
Selected peptides and the transitions can be found in
Supplementary table 2. The isolation width of Q1 was 1.2 Da.
MS2 resolution was 35,000 at an AGC target value of 1 million
at a maximum fill time of 100 ms. LCMS conditions and
gradients were the same as for the data-dependent analyses.
PRM data analysis and data integration were performed in
Skyline 3.6.0.10493. Peptide abundances were calculated by
comparing the peak area of the eluted (light) and the peak
area of the spiked-in heavy peptides.
Mice and vaccination
C57BL/6J mice were purchased from Envigo, Harlan labora-
tories (The Netherlands) at an age of 8–10 weeks and housed
under specified pathogen-free conditions in animal facilities
of the Leiden University Medical Center. All animal experi-
ments were approved by and implemented according to ethi-
cal guidelines of the Dutch Central Animal Experiment
Committee and the Federation of European Laboratory
Animal Science Associations (FELASA). Mice vaccinated
with irradiated (15000 rads) MC-38 where twice injected S.
C. in the right flank with 5 × 106 cells in 200 µL of PBS with
a two-week interval. Animals involved in tumor outgrowth
experiments were S.C. injected in the right flank with 3 × 105
live MC-38 cells in 200 µL PBS. Tumor sizes where measured
2–3 times a week and 1500 mm3 was maintained as humane
endpoint. The method used for the mice treated with anti-PD
-L1 antibodies can be found in the publication of Sow, H.
S. et al.23 Vaccinated mice were injected once with 20 nmol
Adpgk or Rpl18 synthetic peptides intradermally in 50 µL PBS
adjuvanted with 20 µg of CpG (ODN 1826 – TLR9 ligand
InvivoGen tlrl-1826-1) or 10 nmol Rpl18-conjugated with
equimolar Upam-ligand (peptides and Upam where conju-
gated as described previously in).24–26
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In vitro (re-)stimulation
T cell cultures were started with splenocytes from several experi-
ments. Therefore, spleensweremashedon single cell strainerswith
the blunt end of a 5 mL syringe and washed with culture medium.
Cellular precipitates after centrifugation were treated with 5mL of
lysis buffer for 3min. at room temperature to remove erythrocytes
and subsequently washed with culture medium. For the initial
restimulation and expansion of tumor-antigen specific T cells,
5 × 106 splenocytes per well were plated in a 24-wells and co-
cultured with 1 × 105 irradiated (15000 rads) MC-38 cells. After
7 days, debris was separated from living cells with ficol and living
cells were plated at 1 × 105 cells/well in a 24 wells plate in culture
medium reconstituted with 5 Cetus Units (ca. 35 IU) of recombi-
nant human IL-2 permL. Consecutive re-stimulations and expan-
sions were initiated after two weeks of rest with 2 × 106 fresh,
irradiated (3000 rads) splenocytes from naïve mice and 1 × 105
irradiated MC-38 cells. Read-out of T cell specificities was per-
formed through o/n pre-culture of 5 × 104 DC’s of the growth-
factor dependent cross-presenting dendritic cell-line D127 with
5 µM synthetic peptide, whereupon T cells and 2 µg/mL brefeldin
A (Sigma-Aldrich) were added. Synthetic “long” peptides were
designed for optimal synthesis and dissolvability with the muta-
tion located at the central region. Therefore, N- and C-terminal
wild-type sequences were added resulting in peptides of approxi-
mately 20 amino-acids long. The following peptides were designed
and synthesized: SFMAPIDHTTMSDDARTE (Aatf), HL
ELASMTNMELMSSIVHQ (Adpgk), GSNGDPSSPYSLHYL
SPTGVNE (Cpne1), FRRPSTYVIPRLERILLAK (Gtf2i),
RVLELFRAAQLANDVVLQIME (Reps1), KAGGKILTFDR
LALESPK (Rpl18), ARCAQFPRALDKVHYYIKLKD (Tdg),
QYFDAVKNAQHLEVESIPLPD (Wbp11). Direct tumor-recog-
nition assays were done through co-culture of T cells with 1 × 105
live tumor cells in 48-wells flat-bottom in culture medium supple-
mented with 2 µg/mL brefeldin A.
Flow cytometrics
For in vitro peptide stimulation assays, analysis of intracellular
cytokine production (ICS) was started through extracellular
staining of CD3ε (EF450, clone 17A2, eBioscience), CD4
(BV605, clone RM4-5, BioLegend), and CD8α (APC-R700,
clone 53–6.7, BDBiosciences) in FACS buffer (0,5% Bovine
Serum Albumin, 0,02% Sodium Azide). Afterward, cells were
washed and o/n treated with 0.5% paraformaldehyde to subse-
quently be stained with TNFα (FITC, clone MP6-XT22,
eBioscience) and IFNγ (APC, clone XMG1.2, Invitrogen)
through the use of perm/wash (BioLegend). For the analysis of
tumor-infiltrated lymphocytes, whole tumors were resected
from the flank of mice and mashed in 3 mL of serum-free
medium (IMDM medium (Lonza) supplemented with 100 IU/
mL penicillin/streptomycin (Gibco), 2 mM L-glutamine (Gibco)
and 25 µM 2-mercaptoethanol). 500 µL tumor-mash was incu-
bated with 77 µL (stock conc. 2,5 mg/mL) of Liberase TL (Roche)
for 30 min. at 37°C. A single cell suspension was made through
the use of a cell strainer and washed with culture medium.
Tumor material and respective splenocytes were similarly sti-
mulated and stained as described in previous ICSs, although
extracellular and intracellular staining markers now included
CD45 (BV605, clone 30-F11, BioLegend), CD3ε (EF450, clone
17A2, eBioscience), CD4 (PE, clone RM4-5, BioLegend), CD8α
(APC-R700, clone 53–6.7, BDBiosciences), TNFα (FITC, clone
MP6-XT22, eBioscience), and IFNγ (PE-Cy7, clone XMG1.2,
BDBiosciences). Tumor-recognition samples were stained at
room temperature for 15 min. with PE and APC tetramers for
Adpgk and Rpl18, respectively (in-house production with pre-
dicted epitope). Extracellular markers included CD3ε (EF450,
clone 17A2, eBioscience), CD4 (BV605, clone RM4-5,
BioLegend), and CD8α (APC-R700, clone 53–6.7,
BDBiosciences) were added to tetramer stained samples for
5 min. and kept on ice, while intracellular markers TNFα
(FITC, clone MP6-XT22, eBioscience) and IFNγ (PE-Cy7,
clone XMG1.2, BDBiosciences) were stained according to pre-
vious staining methods. Conjugate vaccinated, tumor-bearing
mice were analyzed on blood tetramer staining. Blood from the
tail was kept on ice in heparin tubes to prevent clotting, prior to
the lysis of erythrocytes. Tetramer staining was done according
to the previous tetramer staining protocol, except for a smaller
extracellular staining panel whereby only CD8α (FITC, clone
53–6.7, BioLegend) was used, and without intracellular staining.
All samples were analyzed on a BD Bioscience LSR-II with
FACSDiva for data-capture software. FlowJo vX (FlowJo, LLC)
was used for sample analysis and processing.
Statistical analysis
Graphpad prism v8 was used for statistical analysis. Respective
statistical tests are mentioned in the legends of the figures.
Significance was determined when p-values reached 0.05 or
less. In general, group comparisons were done with (multiple)
student’s t tests, and survival with Gehan-Breslow-Wilcoxon or
log-rank tests.
Results
Identification of potential epitopes
Recent studies have identified several neo-peptide sequences of
the MC-38 adenocarcinoma colorectal cell-line. However, in
explorative experiments with this model (not shown) we could
only detect very low frequencies of endogenous T cell responses
to these neo-epitopes. To identify other potential neo-antigens
underlying the CD8+ T cell response, we independently analyzed
MHC class I presented neo-epitopes in our MC-38 cell line by
combination of whole-exome/RNA sequencing and MHC class
I peptide elution/mass-spectrometry (Figure 1).
DNA exome sequencing data derived from MC-38 cells
was compared to the wild-type DNA sequence obtained
from the tail of C57BL/6J mice. We have identified a total of
16,143 genomic mutations, of which 3,808 resulted in amino
acid coding changes. By subsequent RNA sequencing we
could define a total of 1,661 expressed variants. MHC class
I binding prediction algorithms resulted in a ranking of 1,501
mutated peptide-epitopes with potential binding affinity for
either Kb or Db molecules (suppl. table 1). This set of potential
neo-peptides was analyzed for MHC class I presentation
through specific pulldown of both H-2b alleles, followed by
mass spectrometry of eluted peptides. Sequence length
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distribution analysis of all peptides derived from separate
H-2Kb and −2Db isolates showed the expected binding pre-
ferences of 8-, 9- or 10-mer peptides and the well-established
anchor-binding residues of these MHC class I molecules
(suppl. Fig. 1). Identity of the eluted peptides were confirmed
by spectral similarity of synthetically produced analogues of
these sequences (suppl. Fig 2).
Intersection of sequencing and elution databases resulted
in the identification of eight possible neo-epitopes (Table 1).
These identified neo-antigens ranged from very low to very
high predicted affinities toward MHC class I and, based on
sequencing data, were mostly occurring heterozygously.
Relative expression frequencies of variant RNA followed the
frequencies seen in DNA. Presentation of the wild-type
sequences by MHC class I could not be determined through
elution in most cases. In conclusion, we confirmed the pre-
sence of most of the mutations reported previously28 but we
also detected four novel candidate neo-epitopes.
Endogenous induction of specific t cells upon
tumor-vaccination
To test whether our neo-epitope candidates were relevant and
immunogenic, we vaccinated “wild-type” C57BL/6J mice with
irradiatedMC-38 tumor cells and analyzed tumor-specific CD8+
T cell responses (Figure 2(a)). For readout, we synthesized long
peptides of ca. 20 amino-acid residues of all candidate neo-
epitopes with the mutation located in the central region of the
amino acid sequence. Splenocytes from MC-38-vaccinated mice
were cultured with peptide-pre-incubated DC’s and analyzed by
intracellular cytokine staining of CD8+ T cells. Three out of eight
candidate neo-peptides induced TNFα and IFNγ poly-
functional activation of CD8+ T cells (Figure 2(b)).
Candidate epitope six, derived from a point-mutated
sequence of ribosomal protein L18 (Rpl18), elicited robust acti-
vation of up to 5 percent of CD8+ T cells ex vivo. The second
largest responses were observed by stimulation with the pre-
viously described neo-epitope from ADP-dependent
Glucokinase (Adpgk). A third mutation in Copine-1 (Cpne-1)
also elicited an observable activation of CD8+ T cells in one
mouse. Upon restimulation of splenocytes with irradiated MC-
38 cells in vitro strongly boosted the expansion of Rpl18-specific
CD8+ T cells up to 70 percent (Figure 2(c)). In addition, activa-
tion of CD8+ T cells was observed to a lower extent for Adpgk-
specific T cells, but not for the third candidate Cpne1.
Analysis of poly-functional T cell populations in
tumor-bearing mice
To follow up on endogenously induced CD8+ T cells by
irradiated MC-38, we analyzed endogenous CD8+ T cell spe-
cificities in tumor bearing mice. Therefore we inoculated
untreated mice with MC-38 and eight days after inoculation,
palpable and growing tumors were established subcuta-
neously. These mice were used for analysis of both splenic










Figure 1. Strategy to identify MC-38 colorectal tumor specific neo-peptides. MC-38 DNA was isolated and its sequenced exome was compared to DNA from C57BL/6
wild-type mice for genetic variants. Corresponding amino acid sequences were used to predict potential binders to MHC class I Kb and Db by NetMHC4.0 prediction
algorithm. A combination of immunoprecipitation of MHC class I from MC-38 lysate and subsequent mass-spectrometry of eluted peptides was performed to
establish MHC class I presentation.
Table 1. Selected candidate neo-epitopes. All eight neo-peptides shown were selected by exome and RNA sequencing and confirmed with synthetic peptide mass-
spectrometry for MHC class I presentation. IC50 of presented peptide affinity was predicted with NetMHC (ANN) for respective MHC alleles. Candidate neo-epitopes
indicated with (*) were previously described in Yadav M. et al. (2014). Context of these candidate neo-epitopes was included in the form of variant frequencies in
DNA and RNA, whole gene expression levels in MC-38 (in transcripts per million), and the observed presence of wild-type (WT) peptides in the elution.
# Name Selected peptide WT AA IC50 (nM) MHC allele Variant occurance Variant DNA freq. Variant RNA freq. Expression in MC-38 Eluted WT
1 Aatf* MAPIDHTTM A 90,2 Db Heterozygous 0.49 0.43 5,321 Y
2 Adpgk* ASMTNMELM R 4,3 Db Heterozygous 0.33 0.40 1,391 Y
3 Cpne* SSPYSLHYL D 182,3 Db Heterozygous 0.39 0.40 6,399 N
4 Gtf2i STYVIPRL G 16,5 Kb Heterozygous 0.39 0.53 1,530 N
5 Reps1 AQLANDVVL P 16,2 Db Heterozygous 0.24 0.18 2,486 Y
6 Rpl18 KILTFDRL Q 33,2 Kb Heterozygous 0.35 0.31 15,546 Y
7 Tdg RALDKVHYYI Q 4656,2 Db Heterozygous 0.45 0.48 1,869 N
8 Wbp11 DAVKNAQHL V 892,3 Db Heterozygous 0.36 0.36 4,875 Y
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Ex vivo CD8+ T cell frequencies in both spleen and tumor of
these mice displayed a similar dominant response toward the
mutated Rpl18 epitope. Presence of Adpgk- and Cpne1-specific
T cells was observed as well, although to a lower degree as
observed in the MC-38-vaccinated mice (Figure 3(b)).
Rpl18 dominance in checkpoint-inhibitor protected mice
MC-38 is a well-known tumor model for its reliance on PD-
L1 expression, both on the tumor and its microenvironment,
to suppress immunological pressure.29,30 Treatment of MC-38
bearing mice through anti-PD-L1 checkpoint-inhibition has
thus a strong therapeutic effect on tumor sizes, and often
leads to complete regression and cure. We analyzed several
mice that were cured from established MC-38 tumors by PD-
L1 blockade therapy and had acquired immunological protec-
tion for rechallenge with live MC-38 cells (Figure 4(a) top).
We restimulated splenocytes of these mice with irradiated
MC-38 cells and analyzed CD8+ T cell specificities. Again, we
observed a dominant polyfunctional response to mutated
Rpl18 peptide in all samples (Figure 4(a) bottom). In addition,
we could detect the presence of polyfunctional responses
against mutated Adpgk as well, although to a lesser magnitude










































































































































































































Figure 2. Irradiated MC-38 immunization induces CD8+ T cells specific for candidate neo-epitopes. (a) Mice were prime-boost vaccinated with subcutaneous injection
of 5 × 106 irradiated MC-38 tumor cells. (b) Cytokine production of CD8α+ T lymphocytes through stimulation with synthetic “long” peptide-loaded dendritic cells ex
vivo and (c) after restimulation with irradiated MC-38 cells. (b) and (c) are from two independent experiments, n = 3 for each. Shown are representative cytokine
(IFNγ and TNFα) staining plots from CD8α+ populations (left) and plotted percentages of double-positive IFNγ and TNFα cytokine producing populations of individual
mice (right).
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settings major CD8+ T cell anti-tumor responses against two
predicted and eluted neo-antigens.
Thereupon, we have analyzed the binding affinity of
Rpl18 minimal epitope KILTFDRL to H-2Kb and observed
a similar affinity compared to the chicken ovalbumin epitope
SIINFEKL (suppl. Fig. 3). This allowed us to produce MHC
Kb-KILTFDRL-tetramers in-house to identify Rpl18-specific
T cell populations prior to PD-L1 blockade-induced regres-
sion of tumors (Figure 5(b) left panel, gating strategies in
suppl. Fig 4A). In treated mice, Rpl18-specific T cells were
increased more than two-fold on average in the spleen
(Figure 5(b) middle panel). Resection of the lymph nodes
from the tumor-matched flank revealed a similar trend. In
addition, reactivity of Rpl18-specific T cells matched tetra-
mer+ population sizes (Figure 5(b) right panel). We could
not observe a similar trend for Adpgk- or Cpne1-specific
T cells (Suppl. Fig 4B).
Specific T cell recognition of novel neo-epitopes on MC-38
We next analyzed the specificities of cultured bulk T cells from
protected mice (Figure 4a) and their reactivity toward live MC-
38 tumor cells. Coculture of bulk CD8+ T cells from protected
mice were able to specifically recognize Rpl18 and Adpgk syn-
thetic peptide pre-loaded dendritic cells. Recognition to both
the minimally presented peptide epitope or elongated long
synthetic peptides was shown by cytokine production of specific
CD8+ T cells (Figure 5(a)). In addition, pre-incubation of den-
dritic cells with a wild-type sequence of the Rpl18 peptide, fully
negated the responses induced by the mutated variant (Figure 5
(b)). Thereby authenticating the specificity of these T cells for
a single amino acid substitution of the Rpl18 protein.
Furthermore, both Rpl18- and Adpgk-specific populations
produced significant levels of cytokines upon co-culture with
live cells MC-38 and not to control B16F10 melanoma tumor
cells (Figure 5(c)). However, it should be noted that these
presented neo-epitopes were not observed in a commercially
available MC-38 cell-line (suppl. fig 5A), nor was there any
recognition by our cultured bulk T cell (suppl. fig 5B). In
summary, T cells derived from PD-L1 cured mice recognize
two sequenced and eluted candidate neo-epitopes derived
from the Rpl18 and Adpgk genes in our MC-38, and are
able to specifically recognize live tumor cells.
Tumor growth control in peptide-vaccinated mice
Since the CD8+ T cell response to this novel neo-epitope was
capable of direct tumor cell recognition, we aimed to ther-
apeutically vaccinate mice against the neo-epitope of Rpl18.
Therefore, we synthesized peptides covering the neo-epitope
flanked by natural amino acid sequences.
We tested the effectivity of subcutaneous injection of syn-
thetic long peptide adjuvanted with CpG, eight days post-
inoculation of MC-38 tumor cells when all mice had developed
palpable tumors (Figure 6(a) top). In mice receiving the Rpl18
peptide vaccination, we observed a significantly lower tumor
burden twelve and fourteen days after vaccination compared to
CpG control-injected mice. Tumor burden in mice receiving
Adpgk peptide vaccination was lower than control but did not
result in improved survival (Figure 6(b) bottom). To determine
if the difference between neo-epitope vaccinations was the result
of altering presentation levels, we performed parallel reaction
monitoring (PRM) of peptides ASMTNMELM and KILTFDRL
which revealed that both were present at the same level in our
MHC class I elution (suppl. table 2 and suppl. fig. 6).
Since overall survival wasmodest in Rpl18-vaccinatedmice, we
decided to improve the formulation of our vaccination through
a conjugation with Toll-like receptor (TLR) 2-ligand Upam,
a Pam3CSK4 derivative with improved affinity for TLR-2.
25,31
Similarly as the previous setting, we gave tumor-bearing mice
a Day 8 






































































































Figure 3. Tumor-bearing mice have circulating and tumor-infiltrating CD8+ lymphocytes specific for Rpl18 neo-peptide. (a) Mice were inoculated with 3 × 105 live
MC-38 tumor cells. Lymphocytes isolated from spleen and tumor-infiltrating lymphocytes from the established tumors were stimulated with neo-peptides eight days
post inoculation (n = 4). (b) IFNγ and TNFα cytokine production of CD8α+ T lymphocytes through stimulation with synthetic “long” peptides-loaded dendritic cells;
from a single mouse (left) and all double-cytokine producing summarized (right). Where indicated, statistical significance was determined with student’s t test.
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a single injection of this peptide-based vaccine 8 days post inocu-
lation. Six weeks after vaccination with Upam-Rpl18 synthetic
peptide conjugate, we observed a significantly improved survival
in the vaccinated group compared to a Upam control-injected
group (Figure 6(c)). Complete regression of tumors in mice
44 days after tumor challenge was maintained as no palpable
tumors could be observed until 127 days post inoculation.
Concludingly, these results show that a dominant CD8+ T cell
population targeting the neo-epitope of Rpl18 is relevant for anti-
tumor immunity to MC38.
Discussion
Here we report a detailed analysis of the CD8+ immune
response to the highly mutated MC-38 colorectal tumor cell
line. This cell line is frequently used as an appropriate model
for optimizing and development of new immunotherapeutic
strategies as it is sensitive for most immune checkpoint thera-
pies. We have studied spontaneous CD8+ T cell responses in
tumor-bearing mice, response induction after tumor cell vac-
cination, and after effective PD1 immune checkpoint therapy.



























































































































































































































































b Day 12 





















































































Figure 4. Dominant Rpl18-specific CD8+ populations in immunologically protected mice through PD-L1 checkpoint blockade therapy. (a) Mice bearing palpable
tumors 6 days after inoculation with MC-38 tumor cells were injected thrice with anti-PD-L1 in a three-day interval to induce complete tumor control. At eighty days
post inoculation, mice were re-challenged with MC-38 to confirm immunological protection. Tumor-specific T cells were expanded through co-culture with irradiated
MC-38 tumor cells for one week and analyzed by peptide-loaded dendritic cell stimulation o/n (n = 6). (b) A shortened treatment schedule was used to analyze
Rpl18-specific T cells in mice during tumor regression (left panel). At twelve days post challenge, lymphocytes specific for Rpl18 neo-epitope were observed in
spleens and LN’s through tetramer staining (middle panel) and ICS (right panel). Anti-PD-L1 treatment increased Rpl18-specific T cell frequencies in both lymphoid
organs (n = 7, statistical significance was determined with student’s t test, representative results of two independent experiments).
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In all cases we observed that the CD8+ response was domi-
nated by the point-mutated Rpl18 neo-epitope.
In these three different ex vivo settings of MC-38 exposure
in vivo, we could distinguish a large fraction of CD8+ T cells
to respond to a mutation derived from 60S ribosomal protein
L18 (Rpl18), and to a lesser extent to previously described
epitopes derived from ADP-dependent Glucokinase (Adpgk)
and Copine-1 (Cpne1).28 Upon restimulation, the majority of
samples obtained from all ex vivo settings demonstrated
a striking dominance of Rpl18-specific CD8+ T cells, suggest-
ing a central role in anti-MC-38 immunity. This is supported
by analysis of tumor-infiltrating lymphocytes, in which pri-
marily Rpl18-specific T cells appeared to be present and can
be activated to polyfunctional cytokine production.
TheMC-38model is well-described for its expression of PD-L1
on both the tumor cells and the tumor microenvironment.29,30
Thereby providing an explanation for the lack of tumor control
despite the presence of specific-CD8+ T cells in the tumors.
Splenocytes obtained from several of the cured and immunologi-
cally protected mice were challenged with our peptides, whereby
all samples were dominated by Rpl18-specific T cells, although
Adpgk-specific T cells were substantially present as well. Our
analysis showed that the reactivity against our Rpl18-peptide was
specific for the single amino-acid substitution caused by the
somatic mutation in this gene. Cultured Rpl18-specific T cells
were able to directly recognize MC-38 tumor cells. Moreover, we
could ex vivo stain CD8+ T cells with Rpl18-H-2Kb tetramers in
tumor-bearing mice. This suggested a significant contribution of
Rpl18-specific cytotoxic T cells to immunological control of
MC-38.
The MC-38 model is commonly used to optimize immu-
notherapeutic approaches to prime or re-activate anti-tumor
cytotoxic T cells which can overcome tumor-suppressive

















































































































































































Figure 5. Specificity to mutated peptide and direct recognition of tumor cells. (a) Minimal synthetic neo-peptide was compared to N- and C-terminally extended
“long” peptides in intracellular cytokine staining of activated T cells upon coculture with peptide-loaded dendritic cells. (n = 6, error bars depict SEM) (b) Rpl18-
specific T cell bulks were stimulated with either mutated or wild-type extended peptides to determine specificity to the single amino-acid mutation. (c) In vitro
recognition of live MC-38 vs B16F10 melanoma control tumor cells by tetramer-stained T cells in Rpl18+ (5 out of 6 original bulks) and Adpgk+ (3 out of 6) cultures.
A representative gating-plot of a single culture is shown (top). Tumor-specific single and double cytokine production for both Adpgk and Rpl18-specific T cells is
shown below.
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Figure 6. Therapeutic vaccination with Rpl18 neo-peptide-based vaccinations improves tumor control. (a) Schematic representation of therapeutic vaccination
protocol. 3 × 105 tumor cells were subcutaneously injected in the right flank. Eight days post inoculation, tumors established and a single synthetic neo-peptide
vaccination was given intradermally at the tail-base. (b) Therapeutic vaccination with 10 nmol of extended synthetic peptide harboring neo-epitopes of Adpgk or
Rpl18 delayed outgrowth of MC-38 tumors. At day 20, average tumor size in Adpgk-vaccinated mice was two-fold reduced (279 vs. 563 mm3, P = 0,1894), while
Rpl18 vaccination reduced tumor size nearly 10-fold (60 mm3, P = 0,0163). This trend was maintained 22 days post inoculation (Adpgk: 574 vs. 817 mm3, P = 0,4098;
Rpl18: 102 vs. 817 mm3, P = 0,0083). Subsequent median survival was extended in Rpl18 vaccinated mice (37 vs 23,5 days, P = 0,0445), while no significant extension
was observed for Adpgk-vaccinated mice (26,5 days, P = 0,4244). (Eight mice per group; error bars indicate SEM; multiple t tests and Gehan-Breslow-Wilcoxon test
were used for statistical analysis of tumor size and survival, respectively) (representative results of two independent experiments). (c) To improve vaccination efficacy
we conjugated the Rpl18 neo-peptide to Upam TLR2-ligand (also known as Amplivant®). Therapeutic vaccination with 10 nmol of Rpl18-conjugate against
established tumor significantly improved tumor control and survival compared to Upam-control (P = 0,0174; n = 8 vs n = 7 in control group; log rank tested)
(depicted results are from a single experiment).
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a detailed characterization of the CD8+ neo-epitopes of this
tumor model, in which Rpl18-specific T cells appears to
determine a dominant immune-response accompanied by
lower frequencies against mutated Adpgk and Cpne1. Albeit
speculative, the dominant endogenous immune responses
against the Rpl18-derived neo-epitope may originate from
the constitutive expression of this ribosome associated protein
being part of the protein synthesis machinery. Indeed we did
observe a high gene expression level in our MC-38, although
this did not translate to an equally higher presentation in
MHC class I compared to Adpgk. Nevertheless, the previously
described Adpgk epitope is beyond doubt relevant for vacci-
nation-induced MC-38 tumor control as is observed by sev-
eral groups,28,32,33 including our own experimental data with
specific DNA vaccination.34 In addition, care should be taken
with the origin of the MC-38 cell line, as different lines may
contain other neo-epitopes.
Therapeutic vaccination against Rpl18 using synthetic pep-
tides induced delay of tumor outgrowth and extended survival
although overall survival was not affected. We hypothesized
that a conjugation to an optimized TLR-2 ligand Upam or
Amplivant®25,26,31,35,36 would improve immunogenicity and
survival. As expected, vaccination of MC-38 tumor-bearing
mice with this construct resulted in a significant improvement
of survival when compared to adjuvant alone, thus under-
scoring the relevance of the Rpl18 CD8+ neo-epitope in the
MC-38 colorectal cancer model.
Since the rapid establishment of immune-checkpoint therapy
for cancer patients, an increasing amount of studies determine
the prerequisites and mechanisms underlying application of
these antibodies. It has now been recognized that patients bear-
ing tumors with high mutational loads benefit the most, which
appears to be driven by neo-antigen specific T cells.5–8,11,37,38
Despite the positive outcome for many of these patients, a large
fraction of patients remains unresponsive to these therapies
while risking autoimmune-related disorders. Our characteriza-
tion of endogenous, mutation-specific, responses against MC-38
tumor cells will contribute to investigations and optimizations of
immunotherapeutic strategies against cancer.
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